Document:

Exhibit 10.2

 

THIS EXHIBIT HAS BEEN REDACTED AND IS
THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

 

Execution Version

 

_______________________________________________

 

SECOND AMENDED AND RESTATED 

NOVAVAX PRODUCT LICENSE AGREEMENT 

 

_______________________________________________

 

     

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

SECOND AMENDED AND RESTATED NOVAVAX PRODUCT
LICENSE AGREEMENT

 

This SECOND AMENDED
AND RESTATED NOVAVAX PRODUCT LICENSE AGREEMENT (the “Agreement”) is effective as of the 17th day of July, 2018
(the “Effective Date”), by and between

 

Novavax, Inc., a Delaware corporation
having an address at 20 Firstfield Road, Gaithersburg, MD 20878, United States of America (“Novavax” which expression
shall unless repugnant to the context or meaning thereof mean and include its scuccessors and permitted assigns), and

 

CPL Biologicals Private Limited,
a limited company incorporated under the laws of India having an address at “Cadila Corporate Campus”, Sarkhej-Dholka
Road, Bhat, Ahmedabad - 382210, Gujarat, India (“CPLB” which expression shall unless repugnant to the context
or meaning thereof mean and include its scuccessors and permitted assigns).

 

Novavax and CPLB are referred to herein
each individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS, Novavax
and CPLB had entered into that certain Amended and Restated License Agreement, dated June 29, 2009 (the “First Restated
License Agreement”), concurrently with the Amended and Restated Joint Venture Agreement, dated June 29, 2009, between
Novavax and Cadila Pharmaceuticals Limited (“Cadila”), which relates to the formation, governance and operation
of CPLB as a joint venture between Novavax and Cadila (the “First Restated JV Agreement”).

 

WHEREAS, concurrent
with this Agreement, Novavax, Cadila and CPLB have entered into the Second Amendment and Restatement Joint Venture Agreement (the
“Second Restated JV Agreement”) of the even date herewith.

 

WHEREAS, the
Parties desire to amend and restate the First Restated License Agreement to, among other things:

 

		(i)	expressly permit CPLB to develop certain vaccine products using Novavax’ recombinant nanoparticle
vaccine production technology, antigen specific seed development technology, protein expression and cloning system technology,
in addition to Novavax’ virus-like particle technology;

		(ii)	agree to the initial development by Novavax on behalf of CPLB of four (4) vaccine candidate seeds;
and

		(iii)	grant rights under Novavax’ technology and intellectual property to permit CPLB to develop
and commercialize [* * *] products.

 

    	 	2

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

NOW, THEREFORE,
in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and valuable consideration,
the receipt of which is hereby acknowledged, Novavax and CPLB hereby agree as follows :

 

Article 1.

 

DEFINITIONS

 

Capitalized terms used herein and not otherwise
defined herein shall have the meanings ascribed to them, respectively, in the Second Restated JV Agreement. In addition, as used
herein, the following initially capitalized terms will have the following meanings:

 

		1.1	“Arising Know-How” Any and all Know-How developed, conceived or reduced to practice
solely by or on behalf of one Party or jointly by both Parties during the Development, manufacture or Commercialization of a Licensed
Product during the term of this Agreement by either Party, including, but not limited, to Novavax Technologies Arising Know-How.

 

		1.2	“Commercialization Plan” means the plan developed by CPLB for each Licensed
Product for Steering Committee’s review and approval as described in Section 4.2. Each “Commercialization Plan”
shall specify a multi-year marketing and public relations strategy, operational plans to implement such strategies and any other
significant Commercialization activities with respect to the applicable Licensed Product.

 

		1.3	“CPLB Licensed Rights” means (i) any Know-How owned or Controlled by CPLB that
was developed, conceived or reduced to practice in connection with the performance of the First Restated License Agreement and
any Patents that have issued or will issue therefrom and (ii) Arising Know-How owned or Controlled by CPLB and any Patents that
issue therefrom.

 

		1.4	“Development Plan” means the plan developed by CPLB for each Licensed Product
for the purpose of Steering Committee review and approval as described in Section 4.2. Each “Development Plan” shall
specify preclinical studies (including a toxicology program and other preclinical testing), human clinical trials, manufacturing
scale up, Regulatory Approval strategy and any other significant Development activities, that CPLB plans to perform to obtain Regulatory
Approval of the applicable Licensed Product in the Field in the Territory.

 

    	 	3

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		1.5	“Effective Date” means November 30, 2017.

 

		1.6	“Field” shall mean the prevention or treatment of illness in humans and animals.

 

		1.7	“First Restated License Agreement” has the meaning assigned to it in the recitals
above.

 

		1.8	“IND” means an Investigational New Drug Application, as defined in the US Federal
Food, Drug, and Cosmetic Act, as amended from time to time (21 U.S.C. Section 301 et seq.), together with any rules and
regulations promulgated thereunder, or its foreign equivalent.

 

		1.9	“Know-How” means all tangible and intangible (a) techniques, technology, practices,
trade secrets, inventions (whether patentable or not), methods, protocols, processes, formulas, knowledge, know-how, skill, experience,
records, documents, data and results (including pharmacological, toxicological, non-clinical and clinical test data and results),
analytical and quality control data, results or descriptions, software and algorithms and (b) compositions of matter, cells, cell
lines, assays, animal models and physical, biological or chemical material. Know-How shall in any event exclude any Patents.

 

		1.10	“Licensed Product” means the (i) Existing Vaccine Products, (ii) Additional
Vaccine Candidates, and (iii) CPLB Discovered Candidates. Licensed Products shall include (a) any minor modifications to the products
listed the preceding sentence including, by way of example but not limitation, changes to any excipient, changes arising from a
change in manufacturing process, or change in dosage, or, in the case of (i), (ii) and (ii) above, substitution of one or more
seasonal influenza HAs and/or NAs designated by the CDC or by the corresponding authority in any other country (e.g., the WHO in
India) and (b) any such product used in combination with another active ingredient, antigen or adjuvant.

 

		1.11	“Losses” has the meaning assigned to it in Section 9.1.

 

		1.12	“Materials” has the meaning assigned to it in Section 3.6.

 

		1.13	“Matrix-M Technology” means Novavax’ proprietary saponin-based adjuvant
and any technology related thereto.

 

		1.14	“Novavax Licensed Rights” means the Novavax Patents and Novavax Know-How.

 

		1.15	“Novavax Know-How” means and any and all Know-How, including Arising Know-How,
owned or Controlled by Novavax at any time during the term of this Agreement which is used or embodied in, or necessary for developing
or manufacturing, any Licensed Products, including, without limitation, Novavax Technologies Arising Know-How.

 

    	 	4

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		1.16	“Novavax Patents” means those Patents in the Territory owned or Controlled by
Novavax at any time during the term of this Agreement covering or claiming a Licensed Product and/or the manufacture or use thereof
as specifically listed and identified on Schedule II, which schedule shall be updated from time to time.

 

		1.17	“Novavax Technologies” means Novavax’ proprietary baculovirus insect cell
expression, recombinant nanoparticle vaccine production, antigen specific, protein expression and cloning system technologies and
improvements thereto, but does not include the Matrix-M Technology which shall be licensed to CPLB under a separate license agreement
between the Parties.

 

		1.18	“Novavax Technologies Arising “Know-How” has the meaning assigned to it
in Section 6.2.1.

 

		1.19	“Patent” means any and all (a) issued patents and inventors' certificates and
re-examinations, reissues, renewals, extensions, registrations, substitutions, supplementary protection certificates and term restorations
with respect to any of the foregoing, and (b) pending applications for patents and inventors' certificates and patents that issue
therefrom, including, without limitation, provisional applications, continuations, continuations-in-part, divisional and substitute
applications with respect to any of the foregoing.

 

		1.20	“Program Data” means (a) research, preclinical, clinical, manufacturing and
similar data, information, material and results, (b) Regulatory Approvals and Regulatory Documentation, and (c) sales and marketing
information.

 

		1.21	“Regulatory Authority” means any applicable court, agency, department or other
instrumentality of any foreign, federal, state, county, city or other political subdivision with responsibility for granting any
licenses or approvals necessary for the marketing and sale of pharmaceutical products in the Territory.

 

		1.22	“Regulatory Documentation” means, with respect to a Licensed Product, all filing
and supporting documents created, submitted to a Regulatory Authority, and all data contained therein, including, without limitation,
any IND, BLA, foreign counterparts thereof, investigator's brochures, drug master files, correspondence to and from a Regulatory
Authority, minutes from teleconferences with Regulatory Authorities, registrations and licenses, regulatory drug lists, advertising
and promotion documents shared with Regulatory Authorities, adverse event files, complaint files and manufacturing records.

 

    	 	5

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		1.23	“Representatives” has the meaning assigned to it in Section 6.2.

 

		1.24	“Research Plan” means, on an Additional Vaccine Candidate-by-Additional Vaccine
Candidate basis, a description of the Parties’ respective activities, timelines and objectives with respect to the identification
and selection of an Additional Vaccine Candidate for Development and Commercialization under this Agreement.

 

		1.25	“Second Restated JV Agreement” has the meaning assigned to it in the recitals
above.

 

		1.26	“Services” has the meaning assigned to it in Section 5.1.

 

		1.27	“Term” shall mean the term of this Agreement.

 

		1.28	“Third Party” means a person or entity other than Novavax, CPLB, or any of their
respective Affiliate(s).

 

Article 2.

 

ADDITIONAL VACCINE CANDIDATE 

 

Novavax and CPLB have
identified the Additional Vaccine Candidates. The same are listed in Schedule I. In case any vaccine candidate cannot be developed,
Novavax and CPLB shall mutually agree upon the replacemet vaccine candidate.

 

Article 3.

 

LICENSES

 

		3.1	License Grants to CPLB.

 

		3.1.1.	Existing Vaccine Product and Additional Vaccine Candidate License. Novavax
hereby grants to CPLB an exclusive, fully paid-up, royalty-free, non-transferable, right and license, with a right to grant sublicenses
through multiple tiers (subject to Section 3.3), under the Novavax Licensed Rights during the term of this Agreement to research,
develop, make, have made, use, sell, have sold, offer to sell and import Existing Vaccine Products and Additional Vaccine Candidates
for use in the Field in the Territory. The foregoing license shall be exclusive for Licensed Products in the Territory, even as
to Novavax, provided that Novavax retains the right to perform its obligations under this Agreement and any other agreement between
CPLB and Novavax. CPLB’s rights to sell, have sold, offer to sell and import Existing Vaccine Products and Additional Vaccince
Candidate shall be subject to the restriction to the Novavax Product Territory. 

 

    	 	6

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		3.1.2.	CPLB Discovered Candidate License. Novavax hereby grants to CPLB
a non-exclusive, fully paid-up, royalty-free, non-transferable, right and license, with a right to grant sublicenses through multiple
tiers (subject to Section 3.3), under the Novavax Licensed Rights during the term of this Agreement to research, develop, make,
have made, use, sell, have sold, offer to sell and import CPLB Discovered Candidates for use in the Field in the Territory. CPLB’s
rights to sell, have sold, offer to sell and import CPLB Discovered Candidate shall be subject to the restriction to the Novavax
Product Territory. 

 

		3.1.3.	Trademark License. Novavax hereby grants to CPLB a non-exclusive
license to use its trademark, “Novavax” solely upon Licensed Products (and materials relating thereto) to indicate
that CPLB is a joint venture between Cadila and Novavax. Subject to Section 3.3, the license granted under this Section 3.1.3 shall
include the right to grant sublicenses solely in connection with the grant of a sublicense pursuant to Sections 3.1.1 and 3.1.2
to commercialize a Licensed Product, and any attempt to otherwise grant or authorize any sublicense shall be null and void. All
uses of this trademark by CPLB shall comply with all applicable laws and regulations (including, without limitation, those laws
and regulations particularly applying to the proper use and designation of trademarks in the applicable countries). The ownership
and all goodwill accruing to this trademark arising directly from its use by CPLB shall vest in and inure to the benefit of Novavax.
CPLB hereby acknowledges Novavax’ ownership rights in this trademark in the form existing as of the Effective Date, and accordingly,
agrees that at no time during the Term or thereafter to challenge, or assist others to challenge, such corporate logo owned in
the form existing as of the Effective Date or the registration thereof, or attempt to register any trademarks, marks or trade names
confusingly similar to such corporate logo owned in the form existing as of the Effective Date or thereafter.

 

		3.2	License Grant to Novavax. CPLB hereby grants to Novavax a fully paid-up, royalty-free non-exclusive
right and license, with a right to grant sublicenses through multiple tiers, under the CPLB Licensed Rights, to research, develop,
make, have made, use, sell, have sold, offer to sell and import any products that are not Existing Vaccine Products, Additional
Vaccine Candidates and CPLB Discovered Candidates in the Territory.

 

		3.3	Sublicenses. CPLB may sublicense to others under this Agreement. As a condition to its validity
and enforceability, each sublicense agreement shall: (a) incorporate by reference the terms and conditions of this Agreement,
(b) be consistent with the terms, conditions and limitations of this Agreement, (c) prohibit sublicensee’s further
sublicense of the rights delivered hereunder in any manner that is inconsistent with the terms, conditions and limitations of this
Agreement and (d) name Novavax as an intended third party beneficiary of the obligations under such sublicense agreement without
imposition of obligation or liability on the part of Novavax to the sublicensee. To the extent that any terms, conditions or limitations
of any sublicense agreement are inconsistent with this Agreement, those terms, conditions and limitations are null and void against
Novavax, unless Novavax has approved the sublicense in writing.

 

    	 	7

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		3.4	No Implied Rights or Licenses. No right or license, other than those expressly set forth
in this Agreement are granted to either Party, and no additional rights will be deemed granted to either Party by implication,
estoppel or otherwise. All rights not expressly granted by either Party to the other hereunder are reserved.

 

		3.5	Program Data and Right of Reference. CPLB shall keep complete and accurate notes, accounts
and records of all Program Data with respect to Licensed Products, including the manufacture thereof. Novavax shall have the right
to access, use and reference Program Data related to Licensed Products in the possession or control of CPLB for the Development
and Commercialization of Novavax’ products. CPLB shall provide such cooperation and assistance as reasonably requested by
Novavax from time to time to effectuate the foregoing, including, without limitation by providing access to and disclosure of Program
Data to Novavax and by providing such authorization and consents required for reference to regulatory filings and approvals.

 

		3.5.1.	CPLB shall have the right to access, use and reference Program
Data related to Licensed Products in the possession or control of Novavax for the Development and Commercialization of Licensed
Products. Novavax shall provide such cooperation and assistance as reasonably requested by CPLB from time to time to effectuate
the foregoing, including, without limitation by providing access to and disclosure of Program Data to CPLB and by providing such
authorization and consents required for reference to regulatory filings and approvals.

 

		3.6	Materials. In order to facilitate the Development activities contemplated by this Agreement,
either Party may provide to the other Party certain biological materials Controlled by the supplying Party (collectively, “Materials”)
for use by the other Party in furtherance of such development activities. Except as otherwise provided for under this Agreement,
all such Materials delivered to the other Party, will be used only in furtherance of the Development activities conducted in accordance
with this Agreement, will not be used or delivered to or for the benefit of any Third Party, without the prior written consent
of the supplying Party, and will be used in compliance with all Laws. The Materials supplied under this Agreement must be used
with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as
expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE
OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD
PARTY.

 

    	 	8

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article 4.

 

LICENSED PRODUCT
DEVELOPMENT AND COMMERCIALIZATION

 

		4.1	Responsibility. CPLB will have sole responsibility, at its sole expense, for all Development
and Commercialization of Licensed Products in the Field and Territory in accordance with the terms of this Agreement; provided,
however, the Parties acknowledge and agree that the rights granted to CPLB hereunder with respect to CPLB Discovered Candidates
are non-exclusive and Novavax and or its other licensees may Develop or Commercialize the same or similar products.

 

		4.2	Development and Commercialization Plans. Within [* * *] of the Effective Date with respect
to Existing Vaccine Products and prior to beginning any Development or Commercialization activities with respect to an Additional
Vaccine Candidate or CPLB Discovered Candidate, CPLB shall present to the Steering Committee for its written approval a Development
Plan or Commercialization Plan, as applicable, for each such Licensed Product. The Steering Committee may reasonably request adjustments
to activities described in such Development Plan or Commercialization Plan as a condition to granting its approval. In no event
shall CPLB materially alter a Development Plan or Commercialization Plan without the Steering Committee’s prior written consent.
CPLB shall conduct Development or Commercialization of each Licensed Product in a manner that is materially consistent with the
applicable Development Plan or Commercialization Plan. All clinical trial protocols for Licensed Products conducted shall require
the prior written approval of Novavax.

 

		4.3	Regulatory Affairs. CPLB will be responsible for preparing and submitting Regulatory Documentation,
seeking Regulatory Approvals, and maintaining Regulatory Approvals for Licensed Products in the Field and Territory. As set forth
in Article 5, Novavax will cooperate with CPLB in preparing and filing all such reports.

 

    	 	9

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		4.4	Manufacture and Supply. CPLB will be responsible for the manufacture of Licensed Product
in the Territory and for all costs associated therewith. In accordance with Article 5, Novavax shall provide technical services
for the purposes of enabling CPLB’s manufacturing facility(ies) to comply with good manufacturing practices and all other
applicable standards promulgated by any applicable Regulatory Authority, including, without limitation, the World Health Organization,
U.S. Food and Drug Administration and European Medicines Agency.

 

		4.5	Adverse Event Reporting. CPLB will maintain a record of all non-medical and medical Licensed
Product-related complaints and reports of Adverse Events in the Territory with respect to any Licensed Product Developed or Commercialized
by CPLB. At the request of either Party, Novavax and CPLB shall enter into reasonable and customary pharmacovigilance agreement
with respect to sharing of adverse event data and information for Licensed Products as required to comply with applicable laws
and regulations.

 

		4.6	Development and Commercial Reporting. During the Term of this Agreement, CPLB will provide
annual written progress report to the Steering Committee summarizing the Development and Commercialization of Licensed Product(s)
during the past year. Each such progress report will be provided to the Steering Committee by CPLB no later than December 31 of
each year beginning in 2018.

 

Article 5.

 

NOVAVAX SERVICES

 

		5.1	Technology Transfer Services. [* * *], Novavax shall disclose and provide to CPLB the Novavax
Know-How set forth on Schedule II. As reasonably requested by the CPLB, Novavax shall disclose and provide to the CPLB any improvements
to the such Know-How made by Novavax during the term of this Agreement. To effectuate the transfer and implementation of such Novavax
Know-How, Novavax shall provide the Development and Manufacturing Services set forth on Schedule III (the “Services”).
As soon as practicable after the Effective Date, the Parties shall mutually develop and agree to a reasonable timetable pursuant
to which the Services will be provided.

 

    	 	10

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		5.2	Impracticability. Novavax shall not be obligated to provide any Service to the extent the
performance of such Service becomes commercially impracticable as a result of events or circumstances outside of the control of
Novavax, including, to the extent the performance of such Services would require Novavax to breach any Laws or could reasonably
be expected to result in the breach of any applicable contract, license, or other agreement; provided however, that Novavax represents
and warrants to CPLB that, as of the date of this Agreement, Novavax has no knowledge of any event or circumstance that would cause
the performance of Services to violate any Laws or could reasonably be expected to result in the breach of any applicable contract,
license or other agreement. Novavax shall provide CPLB with reasonable notice of the occurrence of any event which would cause
Novavax to curtail or cease any Service pursuant to this Section 5.2.

 

		5.3	Expenses. CPLB shall reimburse Novavax for its reasonable out-of-pocket expenses incurred
in connection with the performance of the Services hereunder, including travel. By the tenth business day of each month, Novavax
shall submit to CPLB an invoice report showing a list of all out-of-pocket expenses incurred in performance of the Services during
the preceding month. CPLB shall pay all invoices within thirty (30) days of receipt. Late payments shall bear interest at the lesser
of [* * *] or the maximum rate allowed by Laws. All payments due under this Agreement will be made in U.S. dollars by wire transfer
to a bank account designated by Novavax.

 

Article 6.

 

INTELLECTUAL PROPERTY

 

		6.1	Disclosure. During the Term, the Parties will promptly disclose in writing to one another,
and shall cause its Affiliates, licensees and sublicensees to so disclose, all Arising Know-How. Novavax shall also disclose to
CPLB any Know-How within the Novavax Licensed Rights obtained, licensed or generated after the Effective Date which is not included
within the Arising Know-How.

 

		6.2	Ownership. Novavax shall own all Arising Know-How and any other intellectual property that
is conceived and reduced to practice solely by the employees, contractors or agents (collectively, the “Representatives”)
of Novavax or its Affiliates. Subject to Section 6.2.1, CPLB shall own all Arising Know-How and any other intellectual property
that is conceived and reduced to practice solely by the Representatives of CPLB or its Affiliates. Subject to Section 6.2.1, Novavax
and CPLB shall jointly own all Arising Know-How and any other intellectual property that is jointly conceived or reduced to practice
by the Representatives of Novavax or its Affiliates and the Representatives of CPLB or its Affiliates. Inventorship shall be determined
in accordance with applicable U.S. Laws.

 

    	 	11

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		6.2.1.	Notwithstanding the ownership provisions set forth in Section
6.2 above, Novavax shall own all Arising Know-How related to the Novavax Technologies regardless of inventorship (the “Novavax
Technologies Arising Know-How”). Subject to the terms and conditions of this Agreement,
CPLB assigns, transfers and conveys, and agrees to cause its Representatives, its Affiliates, its Affiliates’ Representatives,
its sublicensees and its sublicensees’ Representatives to hereby assign, transfer and convey, to Novavax all of the right,
title and interest of such persons and/or entities, to and under all of the Novavax Technologies Arising Know-How.

 

		6.3	Prosecution and Maintenance of Patents. Novavax shall have the sole and exclusive right
and authority to control the filing, prosecution, maintenance, and renewal of all Novavax Patents and any Patents that result from
(a) Arising Know-How which is owned by Novavax or jointly owned as provided in Section 6.2 or (b) Novavax Technologies Arising
Know-How, at its own expense. CPLB shall have the sole and exclusive right and authority to control the filing, prosecution, maintenance
and renewal of any Patents that result from Arising Know-How owned by CPLB as provided in Section 6.2. The prosecuting Party shall
(i) provide the other Party with copies of all material filings, documentation and correspondence from, sent to or filed with any
patent office in the Territory, and (ii) provide the other Party with a reasonable opportunity to comment upon all filings and
actions with such patent office in advance of submissions to such patent office. For purposes of this Section 6.3, “filing,
prosecution and maintenance” of patents shall be deemed to include, without limitation, appeals to administrative or judicial
entities having jurisdiction over patentability, the conduct of interferences or oppositions, and/or requests for re-examinations,
reissues or extensions of patent terms. CPLB shall, and shall cause its Representatives, its Affiliates, its Affiliates’
Representatives, its sublicensees and its sublicensees’ Representatives, as applicable, to assist and cooperate with Novavax
in filing, prosecuting and maintaining (a) the Patents that result from Arising Know-How jointly owned by both Parties, for which
the reasonable costs and expenses of such assistance and cooperation shall be equally shared by the Parties and (b) the Patents
that result from the Novavax Technologies Arising Know-How, for which the reasonable costs and expenses of such assistance and
cooperation shall be solely borne by Novavax.

 

		6.4	Abandoned Patents. In the event the prosecuting Party determines not to initiate patent
prosecution for any particular patentable Arising Know-How invention or to cease prosecution or maintenance of, or otherwise abandon,
any Patents that are the subject of Section 6.3 in the Territory (which the prosecuting Party may do in its sole discretion), the
prosecuting Party shall provide reasonable prior written notice to the other Party sufficient for the other Party to timely initiate
or take over the prosecution and maintenance of such Patent and timely file any required documents and responses with the relevant
government patent office in such country, and the other Party may elect (in its sole discretion) to prosecute and maintain such
Patent, at such Party's sole expense; provided, however, in the event Novavax decides not to file, prosecute or maintain a Patent
with respect to a Novavax Technologies Arising Know-How, CPLB shall obtain Novavax’ prior written consent before it may file,
prosecute or maintain any such Patent. In such event, upon the request of and, at the expense of the other Party, the prosecuting
Party shall assign to the other Party all of its right, title and interest in, to and under such Patent which the prosecuting Party
has decided to abandon and provide reasonable cooperation to the other Party with respect thereto (including, without limitation,
providing necessary information and executing relevant documents).

 

    	 	12

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		6.5	Enforcement of Patents.

 

		6.5.1	Infringement by Third Parties. In the event that Novavax or CPLB
becomes aware of or has reasonable suspicions of Third Party activities in the Territory that could constitute infringement or
misappropriation of the Novavax Licensed Rights and/or CPLB Licensed Rights, then such Party shall promptly notify the other Party
of such Third Party activities, including identification of such Third Party and delineation of the facts relating to such Third
Party activities. Novavax shall have the right (but shall not be obligated) to enforce the Novavax Licensed Rights and/or CPLB
Licensed Rights against any actual or alleged infringement or misappropriation thereof in the Territory by a Third Party (by bringing
a suit, action or proceeding against such Third Party), at Novavax' sole expense. If Novavax does not enforce such Novavax Licensed
Rights and/or CPLB Licensed Rights by (i) one hundred (100) days following the notice of alleged infringement or (ii) thirty (30)
days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such an action, whichever
comes first, then CPLB shall have the right (but not the obligation) to enforce such Novavax Licensed Rights and/or CPLB Licensed
Rights against any actual or alleged infringement or misappropriation thereof in the Territory by a Party (by bringing a suit,
action or proceeding against such party), at CPLB's sole expense; provided, however, in the event Novavax does not enforce such
Novavax Licensed Rights, CPLB shall obtain Novavax’ prior written consent before it may enforce such Novavax Licensed Rights.
The non-prosecuting Party shall reasonably cooperate with the prosecuting Party in such enforcement activities, at the prosecuting
Party's expense, including by agreeing to be named as a party to (or bringing in its own name) such suit, action or proceeding
for the benefit of the non-prosecuting Party if required for such enforcement action to proceed. The prosecuting Party shall keep
the non-prosecuting Party reasonably informed regarding any such enforcement action and shall consider in good faith the reasonable
comments and suggestions of the non-prosecuting Party related to such suit, action or proceeding. All recoveries received by the
prosecuting Party from any such enforcement action shall be retained by the prosecuting Party.

 

    	 	13

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		6.5.2	Challenge by Third Parties. Novavax and CPLB will each notify
the other Party in writing within ten (10) business days of learning of any alleged or threatened opposition, reexamination request,
action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability of a Patent
under the Novavax Licensed Rights or CPLB Licensed Rights. Owner of the subject Patent will have the right (but not the obligation)
to defend any such challenge in the Territory. If the owner of the subject Patent commences a defense against the alleged or threatened
challenge (i) within sixty (60) days following the detection of the alleged challenge, or (ii) ten (10) business days before the
time limit, if any, set forth in appropriate Laws and regulations for making a filing in defense of such a challenge, whichever
comes first, then the owner of the subject Patent will so notify the other Party promptly. Notwithstanding the foregoing, if any
such action for declaratory judgment, nullity action, or other attack upon the validity, title or enforceability of the Novavax
Licensed Rights or CPLB Licensed Rights includes or will include counterclaims of infringement of the Novavax Licensed Rights or
CPLB Licensed Rights by the Third Party, control of such action or other attack shall be governed by Section 6.5.1.

 

Article 7.

 

CONFIDENTIALITY; PUBLICATION

 

		7.1	Confidentiality. Party will provide its confidential and/or proprietary information to the
to the other Party and that the use and disclosure of such information shall be governed by Article 14 of the Second Restated JV
Agreement which is hereby incorporated by reference.

 

		7.2	Publication.

 

		7.2.1	Subject to this Section 7.2, each Party shall have the right
to publish the data and results related to Licensed Products. Prior to public disclosure or submission for publication of a proposed
publication describing the results of any scientific or clinical activity relating to a Licensed Product, the Party proposing such
publication shall send the other Party by expedited delivery a copy of the proposed publication to be submitted and shall allow
the other Party a reasonable time period (but not more than sixty (60) days from the date of confirmed receipt) in which to determine:

 

    	 	14

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		(i)	whether the proposed publication contains subject matter for which patent or other protection should
be sought (prior to publication of such proposed publication) for the purpose of protecting an invention or

 

		(ii)	whether the proposed publication contains the Confidential Information of such other Party, or

 

		(iii)	whether the proposed publication contains information that is reasonably likely to have a material
adverse impact on the development or commercialization of Licensed Products or any of Novavax’ other products.

 

Following
the expiration of applicable time period for review, the Party proposing such publication shall be free to submit such proposed
publication for publication and publish or otherwise disclose to the public such scientific or clinical results, subject to the
procedures set forth in Section 7.2.2.

 

		7.2.2	If the reviewing Party reviewing believes that the proposed publication
contains any information described in clauses (i) through (iii) in Section 7.2.1 above, then prior to the expiration of the applicable
time period for review, such Party shall notify the publishing Party in writing of such belief. On receipt of written notice from
the reviewing Party that such proposed publication contains:

 

		(i)	its Confidential Information, the publishing Party shall remove such Confidential Information from
such proposed publication prior to any publication thereof, unless the other Party agrees otherwise in writing; or

 

		(ii)	the publishing Party shall delay public disclosure of such information or submission of the proposed
publication for an additional period of thirty (30) days to permit preparation and filing of a patent application on such invention;
or

 

		(iii)	the Parties shall mutually agree on how to proceed with the publication of such information in
compliance with all applicable laws and regulations.

 

    	 	15

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article 8.

 

REPRESENTATIONS AND WARRANTIES

 

		8.1	Mutual Representation and Warranties. Each of Novavax and CPLB hereby represents, warrants
and covenants to the other as of the Effective Date that:

 

		8.1.1	It is duly organized, validly existing and in good standing under
the Laws of its jurisdiction of organization and has the corporate power to enter into this Agreement and to perform its obligations
hereunder;

 

		8.1.2	the execution, delivery and performance of this Agreement by
it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may
be bound, nor violate any Laws of any governmental authority having jurisdiction over it;

 

		8.1.3	it shall perform any activities in connection with this Agreement
in compliance with Law.

 

		8.1.4	it has not granted, and during the Term it will not grant, any
right to any Third Party that would conflict with the rights granted to the other Party hereunder; and

 

		8.1.5	it has (or will have at the time performance is due) maintained
and will maintain and keep in full force and effect all agreements necessary to perform its obligations hereunder.

 

		8.2	Representations by Novavax. In addition to the representations and warranties made in Section
8.1, Novavax hereby represents, warrants and covenants to CPLB that as of the Effective Date:

 

		8.2.1	the Novavax Licensed Rights are subsisting and are not the subject
of any interference, re-issue, re-exam, opposition or appeal proceedings;

 

		8.2.2	no Third Party has filed, pursued or maintained or, to its knowledge,
threatened in writing to file, pursue or maintain any claim, lawsuit, charge or other action involving any Licensed Right including
any claim, lawsuit, charge, or action alleging that any Licensed Right is invalid or unenforceable;

 

		8.2.3	all employees and agents of Novavax who have performed any activities
on its behalf in connection with research regarding the Novavax Licensed Rights have properly assigned to Novavax the whole of
their rights in any intellectual property made, discovered or developed by them as a result of such research, and no Third Party
has any rights to any such intellectual property; and

 

    	 	16

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		8.2.4	the Novavax Licensed Rights are free and clear of any liens,
charges, encumbrances or rights of others, to possession or use that may interfere with Novavax’ possession or use under
this Agreement.

 

		8.3	Representations by CPLB. In addition to the representations and warranties made in Section
8.1, CPLB hereby represents, warrants and covenants to Novavax that as of the Effective Date:

 

		8.3.1	it and its Affiliates are not debarred
or disqualified under (i) the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or any foreign equivalent or (ii) any
government programs, including, without limitation Medicare, Medicaid or their foreign equivalents, and it does not, and will not
during the Term, employ or use the services of any person who is so debarred or disqualified in the performance of this Agreement,
and in the event that CPLB becomes aware of such debarment or disqualification or threatened debarment or disqualification of it,
its Affiliates or any person providing services to CPLB, including services to its Affiliates or sublicensees, that directly or
indirectly relate to activities contemplated by this Agreement, CPLB shall immediately notify the Novavax in writing and CPLB shall
cease using any such person to perform any such services.

 

		8.3.2	the CPLB Licensed Rights are subsisting
and are not the subject of any interference, re-issue, re-exam, opposition or appeal proceedings; and

 

		8.3.3	the CPLB Licensed Rights are free and
clear of any liens, charges, encumbrances or rights of others, to possession or use that may interfere with CPLB’s possession
or use under this Agreement.

 

		8.4	DISCLAIMER OF WARRANTIES. Except as expressly set forth herein, EACH PARTY EXPRESSLY DISCLAIMS
ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.
Without limiting the generality of the foregoing, each Party expressly does not warrant, and disclaims any warranties with regards
to: (a) the success of any study or test commenced under this Agreement, (b) the safety or usefulness for any purpose of the technology
or materials it provides or discovers under this Agreement; and/or (c) the validity, enforceability, or non-infringement of any
intellectual property rights or technology it provides or licenses to the other Party under this Agreement.

 

    	 	17

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article 9.

 

INDEMNIFICATION, INSURANCE AND LIMITATION
OF LIABILITY

 

		9.1	Indemnification by CPLB. CPLB will indemnify, defend and hold harmless Novavax, its Affiliates,
and their respective Representatives from and against any and all liability, loss, damage or expense (including without limitation
reasonable attorney’s fees) it may suffer as the result of claims, demands, actions and proceedings brought against it by
any Third Party (collectively, “Losses”) to the extent such Losses result from the (a) negligence or willful
misconduct by CPLB, its Affiliates or its sublicensees, or their respective Representatives, (b) material breach by CPLB of its
representations, warranties or covenants contained within this Agreement or (c) manufacture, use, sale, or offer for sale of a
Licensed Product in the Territory due to a design defect or a manufacturing defect, including but not limited to, a Loss related
to the death of or injury to a Third Party. CPLB's obligation to indemnify any such indemnitee pursuant to this Section 9.1 will
not apply to the extent of any Loss that arises from the (i) material breach by Novavax of its representations, warranties or covenants
contained within this Agreement, or (ii) negligence or willful misconduct of any such indemnitee.

 

		9.2	Indemnification by Novavax. Novavax will indemnify, defend and hold harmless CPLB, its Affiliates,
and their respective Representatives from and against any and all Losses to the extent such Losses result from the (a) negligence
or willful misconduct by Novavax or its Affiliates, or their respective Representatives, or (b) material breach by Novavax of its
representations, warranties or covenants contained within this Agreement. Novavax' obligation to indemnify any such indemnitee
pursuant to this Section 9.2 will not apply to the extent of any Loss that arises from the (i) material breach by CPLB of its representations,
warranties or covenants contained within this Agreement or (ii) negligence or willful misconduct of any such indemnitee.

 

		9.3	Procedures. An indemnitor’s agreement to indemnify, defend and hold harmless an indemnitee
hereunder is conditioned on such indemnitee (a) providing prompt written notice of any claim giving rise to an indemnification
obligation hereunder but only if a failure to so notify causes prejudicial harm to the indemnitor's ability to defend, (b) permitting
indemnitor to assume full responsibility to investigate, prepare for and defend against any such claim, (c) providing reasonable
assistance in the defense of such claim at indemnitor's reasonable expense, and (d) not compromising or settling such claim without
indemnitor's advance written consent. An indemnitee may participate, at its expense and using its own counsel, in the indemnitor’s
defense of a claim under this Article 9. 

 

    	 	18

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		9.4	Insurance. CPLB shall procure and maintain insurance, including product liability insurance,
adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly
situated at all times during which any Licensed Product is Developed or Commercialized by CPLB, its Affiliates or sublicensees.
It is understood that such insurance shall not be construed to create a limit on CPLB’s liability with respect to its indemnification
obligations under this Article 9. CPLB shall provide Novavax with written evidence of such insurance upon request. CPLB shall provide
the Novavax with written notice at least thirty (30) days prior to the cancellation, non-renewal or material change in such
insurance.

 

		9.5	Limitation of Liability. EXCEPT TO THE EXTENT (A) SUCH PARTY MAY BE REQUIRED TO INDEMNIFY
THE OTHER PARTY UNDER THIS ARTICLE OR (B) AS REGARDS A BREACH OF A PARTY'S RESPONSIBILITIES PURSUANT TO ARTICLE 7, NEITHER PARTY
NOR ITS RESPECTIVE AFFILIATES WILL BE LIABLE TO THE OTHER PARTY FOR ANY LOSS OF PROFITS, LOSS OF BUSINESS OR INTERRUPTION OF BUSINESS,
OR FOR ANY OTHER INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES UNDER THIS AGREEMENT, WHETHER IN CONTRACT,
WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGES.

 

Article 10.

 

TERM; BREACH

 

		10.1	Term and Termination. The term of this Agreement will commence on the Effective Date and
will continue until (a) CPLB provides one-hundred twenty (120) days prior written notice of termination to Novavax, (b) the Parties
mutually agree in writing to terminate the Agreement, (c) either Party is in material breach of or
default under this Agreement and has not cured such breach or default within ninety (90) days after written notice from the other
Party specifying the nature of such breach or default in reasonable detail, (d) date of receipt of a written notice of termination
from one Party if the other Party is subject to an insolvency or bankruptcy proceeding being commenced against such Party,
or such Party commences such proceeding, or such Party ceases to conduct business in the normal course or making an assignment
for the benefit of its creditors; or (e) the termination of the Second Restated JV Agreement.

 

    	 	19

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		10.2	Survival and Consequences of Termination. The following provisions of this Agreement shall
survive expiration or termination of this Agreement for any reason: Articles 7, 9 and 10 and Sections 3.5, 6.2 and 8.5.

 

		10.2.1	In the event that this Agreement is terminated under Section
10.1(a) or under Section 10 (d) with respect to CPLB, the license grant under Section 3.2 shall survive. 

 

		10.2.2	In the event that this Agreement is terminated under Section
10.1 (c) due to Novavax’ breach or default hereunder or under Section 10.1(d) with respect to Novavax, the license grants
under Sections 3.1 shall survive.

 

		10.2.3	In the event that this Agreement is terminated under Section
10.1(c) due to CPLB’s breach or default hereunder, (i) the license grant under Section 3.2 shall survive, (ii) upon Novavax’
written request, CPLB shall grant to Novavax an exclusive, worldwide, royalty-free, paid-up license under all trademarks and trade
names (including an application, extension or renewal thereof) applicable to all Licensed Products, (iii) upon Novavax’ written
request, CPLB shall execute any document reasonably necessary to transfer to Novavax all Program Data to continue the Development
or Commercialization of all Licensed Products, (iv) upon Novavax’ written request, CPLB shall transfer any studies in progress
pursuant to the Development Plan to Novavax in a manner that allows such studies to continue uninterrupted to the extent reasonable
and practical, (v) CPLB will assign to Novavax, to the extent assignable and upon Novavax’ written request, CPLB’s
rights in any or all Third Party agreements regarding licenses, sublicenses, services or supplies related to the Development or
Commercialization of Licensed Products, including without limitation any agreements with a Third Party regarding the manufacture
of Licensed Products, (vii) to the extent that any agreement in the preceding clause is not assignable by CPLB, then such agreement
will not be assigned, and upon the written request of Novavax, CPLB will use commercially reasonable efforts to allow Novavax to
obtain and to enjoy the benefits of such agreement in the form of a license or other right to the extent held by CPLB subject to
such Third Party’s rights, and (vii) CPLB will, at the [* * *], if CPLB sources
such Product from a Third Party, or at [* * *], if CPLB or any of its Affiliates manufactures
the Licensed Product, supply Novavax with commercial quantities of Licensed Products in the dosage strength, formulation and presentation
under Development or being Commercialized by CPLB, in either case, as of the effective date of termination until the earlier of
(A) six (6) months after the effective date of termination or (B) establishment by Novavax of an alternative supply for such Product
on commercially reasonable terms. 

 

    	 	20

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article 11.

 

DISPUTE RESOLUTION

 

		11.1	Disputes. The Parties recognize that disputes as to certain matters may from time to time
arise during the Term which relate to either Party's rights and/or obligations hereunder. It is the objective of the Parties to
establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation
and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article
11 if and when a dispute arises under this Agreement.

 

		11.2	Arbitration. Any dispute arising between the Parties out of or in connection with the implementation
or interpretation of this Agreement shall, if not settled amicably within ninety (90) days from the date that the dispute arose,
be finally settled by three (3) arbitrators. Each Party shall be entitled to appoint one (1) arbitrator and the two (2) so appointed
shall appoint the third arbitrator in accordance with the Arbitration and Conceliation Act, 1996 as at present in force. The language
of the arbitration proceedings shall be English and its place shall be Singapore. The arbitral award or determination shall be
final and subject to no appeal and shall deal with the question of costs of arbitration and all matters related thereto.

 

The Parties agree that it would
be impossible or inadequate to measure and calculate their damages from any breach of the Agreement though great and irreparable.
Accordingly, each Party agrees that if the other Party breaches this Agreement, the non-breaching Party will have available, in
addition to any other right or remedy available, the right to obtain an injunction from a court of competent jurisdiction restraining
such breach or threatened breach and specific performance of any provision of this Agreement.

 

		11.3	Award. Each Party will abide by any arbitral award rendered pursuant to this Article 11.
If a Party resists enforcement of an arbitral award, any costs, fees or taxes incident to enforcement will be charged against that
Party to the extent permitted by Law. Each Party will bear its own legal fees for arbitration, and the arbitrator(s) will assess
their costs, fees and expenses against the Party losing the arbitration.

 

		11.4	Confidentiality. Any arbitration proceeding, including without limitation the existence
of any dispute submitted to arbitration and any arbitral award or decision, will be Confidential Information of both Parties, and
the arbitrator(s) will issue appropriate protective orders to safeguard each Party’s Confidential Information, provided that
such Confidential Information may be disclosed solely as necessary in connection with the enforcement of an arbitral award or as
otherwise required by Laws (subject to Article 7).

 

    	 	21

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article 12.

 

MISCELLANEOUS

 

		12.1	Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of India.

 

		12.2	Entire Agreement. Subject to this Section 12.2, this Agreement shall amend and restate in
its entirety the First Restated License Agreement; provided, however, such amendment and restatement shall not affect
any rights or obligations of the Parties that accrued under the First Restated License Agreement prior to the Effective Date. Subject
to the preceding sentence, this Agreement (including its Exhibits) sets forth all the covenants, promises, agreements, warranties,
representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes and
terminates all prior agreements and understanding between the Parties with respect to such subject matter. No subsequent alteration,
amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by the respective
authorized officers of the Parties.

 

		12.3	Third Party Contractors. Notwithstanding the Second Restated JV Agreement, the Parties will
perform their obligations under this Agreement as third party contractors and nothing contained in this Agreement will be construed
to be inconsistent with such relationship or status. This Agreement will not constitute, create or in any way be interpreted as
a joint venture or partnership of any kind.

 

		12.4	Notices. Any notice, request, demand, waiver, consent, approval or other communication permitted
or required under this Agreement will be in writing, will refer specifically to this Agreement and will be deemed given only if
sent by electronic mail (with receipt confirmed), facsimile transmission (with transmission confirmed) or by an internationally
recognized delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified
in this Section 12.4 or to such other address as the Party to whom notice is to be given may have provided to the other Party in
accordance with this Section 12.4. Any notice delivered by electronic mail or facsimile will be confirmed by a hard copy delivered
as soon as practicable thereafter by an internationally recognized overnight delivery service. Such notice will be deemed to have
been given on the second business day (at the place of delivery) after deposit with an internationally recognized delivery service.

 

    	 	22

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

	If to Novavax:	Novavax, Inc.
	 	20 Firstfield Road
	 	Gaithersburg, MD 20878
	 	attn: General Counsel
	 	Email : jherrmann@novavax.com
	 	Facsimile No. : 240-268-2010
	 	 
	If to CPLB:	CPL Biologicals Private Limited
	 	Cadila Corporate Campus
	 	Sarkhej-Dholka Road
	 	Bhat, Ahmedabad- 382210
	 	Gujarat, India
	 	Attn: Dr. Rajiv I. Modi, Chairman
	 	Email: rimodi@ cadilapharma.co.in
	 	Facsimile No.: +91 (02718) 225031

 

		12.5	Assignment.

 

		12.5.1	Novavax may not assign this Agreement, in whole or in part, without
the advance written consent of CPLB; provided, however, that this Agreement shall be automatically assigned to Novavax’ successor
in connection with the acquisition, merger or sale of Novavax or the sale, transfer, lease, assignment or disposal of all or substantially
all of the property or assets of Novavax to which this Agreement relates, whether by way of a single transaction or a series of
related transactions, and such successor shall be fully bound by the terms and conditions hereof.

 

		12.5.2	CPLB may not assign this Agreement, in whole or in part, without
the advance written consent of Novavax; provided, however, that this Agreement shall be automatically assigned to CPLB's successor
in connection with the sale, transfer, lease, assignment or disposal of all or substantially all of the property or assets of CPLB,
whether by way of a single transaction or a series of related transactions, including a Change in Control of CPLB (as that term
is defined in Schedule II of the Second Restated JV Agreement), and such successor shall be fully bound by the terms and conditions
hereof; provided that any such automatic assignment by CPLB within the scope of Schedule II of the Second Restated JV Agreement
shall only be effective if such transaction was approved by Novavax under and pursuant to the Second Restated JV Agreement for
so long as such approval rights of Novavax under the Second Restated JV Agreement have not been terminated.

 

    	 	23

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

		12.5.3	Any assignment or purported assignment by either Party in violation
of this Section 12.5 will be null and void.

 

		12.6	Force Majeure. No Party shall be in default of this Agreement by reason of its failure or
delay in complying with its obligations under this Agreement if such failure or delay is caused by matters out of its reasonable
control, including but not limited to acts of God, changes in Laws, strikes, lock-outs, fire, riots, or civil war or civil commotion;
provided that such Party gives the other Party prompt written notice of the failure or delay in performance and the reason therefor
and uses its reasonable efforts to limit the resulting failure or delay in its performance.

 

		12.7	Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular
article or section.

 

		12.8	No Strict Construction. This Agreement has been prepared jointly and will not be strictly
construed against either Party.

 

		12.9	Ambiguities. Ambiguities and uncertainties in this Agreement, if any, will not be interpreted
against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.

 

		12.10	English Language. All notices required or permitted to be given hereunder, and all written,
electronic, oral or other communications between the Parties regarding this Agreement will be in the English language. This Agreement
is in the English language only, which language will be controlling in all respects, and all versions hereof in any other language
will be for accommodation only and will not be binding upon the Parties.

 

		12.11	No Waiver. Any delay in enforcing a Party's rights under this Agreement or any waiver as
to a particular default or other matter will not constitute a waiver of such Party's rights to the future enforcement of its rights
under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period
of time.

 

		12.12	Severability. If one or more of the provisions in this Agreement are deemed unenforceable
by Law, then such provision will be deemed stricken from this Agreement and the remaining provisions will continue in full force
and effect and shall be interpreted to give full effect to the commercial agreement between the Parties.

 

		12.13	Counterparts. This Agreement may be executed in one or more identical counterparts, each
of which will be deemed to be an original, and which collectively will be deemed to be one and the same instrument.

 

    	 	24

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

IN WITNESS WHEREOF, the Parties have by
duly authorized persons executed this Agreement as of the Effective Date.

 

	Novavax, Inc.	 	CPL Biologicals Private Limited
	 	 	 	 	 
	By :	/s/ Stanley C. Erck	 	By :	/s/ Dr. Rajiv I Modi
	Stanley C. Erck	 	Dr. Rajiv I Modi
	President & CEO	 	Chairman 

 

    	 	25

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Schedule I

 

Additional Vaccine Candidates

 

Additonal Vaccine Candidate shall mean the following:

 

[* * *]

 

    	 	26

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Schedule II

 

	Docket No.

Family	 	Application No.	 	Country	 	Title
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]
	[* * *]	 	[* * *]	 	[* * *]	 	 

 

    	 	27

    THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Schedule III

 

Development and Commercialization Services

 

[* * *]

 

    	 	28ubx-ex101_206.htm

Exhibit 10.1

UNITY BIOTECHNOLOGY, INC.
AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN
(amended and restated effective as of September 4, 2018)

ARTICLE I.
PURPOSE, SCOPE and administration OF THE PLAN

1.1Purpose and Scope.  The purpose of the Unity Biotechnology, Inc. Amended and Restated 2018 Employee Stock Purchase Plan, as it may be amended from time to time, (the “Plan”) is to assist employees of Unity Biotechnology, Inc., a Delaware corporation, (the “Company”) and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries.  This Plan amends and restates in its entirety the Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan. 

ARTICLE II.
Definitions

Whenever the following terms are used in the Plan, they shall have the meaning specified below unless the context clearly indicates to the contrary. The singular pronoun shall include the plural where the context so indicates.

2.1 “Administrator” shall mean the Committee, or such individuals to which authority to administer the Plan has been delegated under Section 7.1 hereof.

2.2“Agent” means the brokerage firm, bank or other financial institution, entity or person(s), if any, engaged, retained, appointed or authorized to act as the agent of the Company or an Employee with regard to the Plan.

2.3“Board” shall mean the Board of Directors of the Company.

2.4“Code” shall mean the Internal Revenue Code of 1986, as amended.

2.5“Committee” shall mean the Compensation Committee of the Board.

2.6“Common Stock” shall mean the common stock of the Company.

2.7“Company” shall have such meaning as set forth in Section 1.1 hereof.

2.8“Compensation” of an Employee shall mean the regular earnings or base salary paid to the Employee from the Company on each Payday as compensation for services to the Company or any Designated Subsidiary, before deduction for any salary deferral contributions made by the Employee to any tax-qualified or nonqualified deferred compensation plan, including overtime, shift differentials, vacation pay, salaried production schedule premiums, holiday pay, jury duty pay, funeral leave pay, paid time off, military pay and prior week adjustments, but excluding bonuses, commissions, education or tuition reimbursements, imputed income arising under any group insurance or benefit program, travel expenses, business and moving reimbursements, including tax gross ups and taxable mileage allowance, income received in connection with any stock 

 

Amended & Restated ESPP Sept 4, 2018

 

options, restricted stock, restricted stock units or other compensatory equity awards and all contributions made by the Company or any Designated Subsidiary for the Employee’s benefit under any employee benefit plan now or hereafter established. Such Compensation shall be calculated before deduction of any income or employment tax withholdings, but shall be withheld from the Employee’s net income.  

2.9“Designated Subsidiary” shall mean each Subsidiary that has been designated by the Board or Committee from time to time in its sole discretion as eligible to participate in the Plan, including any Subsidiary in existence on the Effective Date and any Subsidiary formed or acquired following the Effective Date, in accordance with Section 7.2 hereof.

2.10“Effective Date” shall mean the date immediately prior to the date Company’s registration statement relating to its initial public offering becomes effective, provided that the Board has adopted the Plan prior to or on such date, subject to approval of the Plan by the Company’s stockholders.

2.11 “Eligible Employee” shall mean an Employee who (a) is customarily scheduled to work at least twenty (20) hours per week, (b) whose customary employment is more than five (5) months in a calendar year and (c) after the granting of the Option would not be deemed for purposes of Section 423(b)(3) of the Code to possess five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Subsidiary. For purposes of clause (c), the rules of Section 424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock which an Employee may purchase under outstanding options shall be treated as stock owned by the Employee. Notwithstanding the foregoing, the Administrator may exclude from participation in the Plan as an Eligible Employee (x) any Employee that is a “highly compensated employee” of the Company or any Designated Subsidiary (within the meaning of Section 414(q) of the Code), or that is such a “highly compensated employee” (A) with compensation above a specified level, (B) who is an officer and/or (C) is subject to the disclosure requirements of Section 16(a) of the Exchange Act and/or (y) any Employee who is a citizen or resident of a foreign jurisdiction (without regard to whether they are also a citizen of the United States or a resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) if either (i) the grant of the Option is prohibited under the laws of the jurisdiction governing such Employee, or (ii) compliance with the laws of the foreign jurisdiction would cause the Plan or the Option to violate the requirements of Section 423 of the Code; provided that any exclusion in clauses (x), and/or (y) shall be applied in an identical manner under each Offering Period to all Employees of the Company and all Designated Subsidiaries, in accordance with Treasury Regulation Section 1.423-2(e).  

2.12“Employee” shall mean any person who renders services to the Company or a Designated Subsidiary in the status of an employee within the meaning of Section 3401(c) of the Code. “Employee” shall not include any director of the Company or a Designated Subsidiary who does not render services to the Company or a Designated Subsidiary in the status of an employee within the meaning of Section 3401(c) of the Code. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on military leave, sick leave or other leave of absence approved by the Company or Designated Subsidiary and meeting the requirements of Treasury Regulation Section 1.421-1(h)(2). Where the period of leave exceeds three (3) months, or such other period specified in Treasury Regulation Section 1.421-1(h)(2), and the individual’s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three (3)-month period, or such other period specified in Treasury Regulation Section 1.421-1(h)(2).

2

Amended & Restated ESPP Sept 4, 2018

 

 

2.13“Enrollment Date” shall mean the first date of each Offering Period.

2.14“Exercise Date” shall mean the last Trading Day of each Offering Period, except as provided in Section 5.2 hereof.

2.15“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

2.16“Fair Market Value” shall mean, as of any date, the value of Common Stock determined as follows:

(a)If the Common Stock is (i) listed on any established securities exchange (such as the New York Stock Exchange, the NASDAQ Global Market and the NASDAQ Global Select Market), (ii) listed on any national market system or (iii) listed, quoted or traded on any automated quotation system, its Fair Market Value shall be the closing sales price for a share of Common Stock as quoted on such exchange or system for such date or, if there is no closing sales price for a share of Common Stock on the date in question, the closing sales price for a share of Stock on the last preceding date for which such quotation exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable;

(b)If the Common Stock is not listed on an established securities exchange, national market system or automated quotation system, but the Common Stock is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the high bid and low asked prices for such date or, if there are no high bid and low asked prices for a share of Common Stock on such date, the high bid and low asked prices for a share of Common Stock on the last preceding date for which such information exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or

(c)If the Common Stock is neither listed on an established securities exchange, national market system or automated quotation system nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith.

2.17“Grant Date” shall mean the first Trading Day of an Offering Period.

2.18 “New Exercise Date” shall have such meaning as set forth in Section 5.2(b) hereof. 

2.19“Offering Period” shall mean such period of time commencing on such date(s) as determined by the Board or Committee, in its sole discretion, and with respect to which Options shall be granted to Participants.  The duration and timing of Offering Periods may be established or changed by the Board or Committee at any time, in its sole discretion.  Notwithstanding the foregoing, in no event may an Offering Period exceed twenty-seven (27) months. 

2.20“Option” shall mean the right to purchase shares of Common Stock pursuant to the Plan during each Offering Period. 

2.21“Option Price” shall mean the purchase price of a share of Common Stock hereunder as provided in Section 4.2 hereof.

2.22“Parent” means any entity that is a parent corporation of the Company within the meaning of Section 424 of the Code and the Treasury Regulations thereunder.

3

Amended & Restated ESPP Sept 4, 2018

 

 

2.23“Participant” shall mean any Eligible Employee who elects to participate in the Plan.

2.24“Payday” shall mean the regular and recurring established day for payment of Compensation to an Employee of the Company or any Designated Subsidiary.

2.25“Plan” shall have such meaning as set forth in Section 1.1 hereof.

2.26“Plan Account” shall mean a bookkeeping account established and maintained by the Company in the name of each Participant. 

2.27“Section 423 Option” shall have such meaning as set forth in Section 3.1(b) hereof.

2.28“Subsidiary” shall mean any entity that is a subsidiary corporation of the Company within the meaning of Section 424 of the Code and the Treasury Regulations thereunder. In addition, with respect to any sub-plans adopted under Section 7.1(d) hereof which are designed to be outside the scope of Section 423 of the Code, Subsidiary shall include any corporate or noncorporate entity in which the Company has a direct or indirect equity interest or significant business relationship.

2.29“Trading Day” shall mean a day on which the principal securities exchange on which the Common Stock is listed is open for trading or, if the Common Stock is not listed on a securities exchange, shall mean a business day, as determined by the Administrator in good faith.

2.30“Withdrawal Election” shall have such meaning as set forth in Section 6.1(a) hereof.

 

ARTICLE III.
PARTICIPATION

3.1Eligibility.  

(a)Any Eligible Employee who shall be employed by the Company or a Designated Subsidiary on a given Enrollment Date for an Offering Period shall be eligible to participate in the Plan during such Offering Period, subject to the requirements of Articles IV and V hereof, and the limitations imposed by Section 423(b) of the Code and the Treasury Regulations thereunder.

(b)No Eligible Employee shall be granted an Option under the Plan which permits the Participant’s rights to purchase shares of Common Stock under the Plan, and to purchase stock under all other employee stock purchase plans of the Company, any Parent or any Subsidiary subject to the Section 423 of the Code (any such Option or other option, a “Section 423 Option”), to accrue at a rate which exceeds $25,000 of fair market value of such stock (determined at the time the Section 423 Option is granted) for each calendar year in which any Section 423 Option granted to the Participant is outstanding at any time. For purposes of the limitation imposed by this subsection, 

4

Amended & Restated ESPP Sept 4, 2018

 

 

(i)the right to purchase stock under a Section 423 Option accrues when the Section 423 Option (or any portion thereof) first becomes exercisable during the calendar year, 

(ii)the right to purchase stock under a Section 423 Option accrues at the rate provided in the Section 423 Option, but in no case may such rate exceed $25,000 of fair market value of such stock (determined at the time such option is granted) for any one calendar year, and 

(iii)a right to purchase stock which has accrued under a Section 423 Option may not be carried over to any other Section 423 Option; provided that Participants may carry forward amounts so accrued that represent a fractional share of stock and were withheld but not applied towards the purchase of Common Stock under an earlier Offering Period, and may apply such amounts towards the purchase of additional shares of Common Stock under a subsequent Offering Period.

The limitation under this Section 3.1(b) shall be applied in accordance with Section 423(b)(8) of the Code and the Treasury Regulations thereunder.

3.2Election to Participate; Payroll Deductions

(a)Except as provided in Section 3.3 hereof, an Eligible Employee may become a Participant in the Plan only by means of payroll deduction. Each individual who is an Eligible Employee as of an Offering Period’s Enrollment Date may elect to participate in such Offering Period and the Plan by delivering to the Company a payroll deduction authorization no later such period of time prior to the applicable Enrollment Date as determined by the Administrator, in its sole discretion.  

(b)Subject to Section 3.1(b) hereof, payroll deductions (i) shall be equal to at least one percent (1%) of the Participant’s Compensation as of each Payday of the Offering Period following the Enrollment Date, but not more than the lesser of fifteen percent (15%) of the Participant’s Compensation as of each Payday of the Offering Period following the Enrollment Date or $50,000 per Offering Period; and (ii) may be expressed either as (A) a whole number percentage, or (B) a fixed dollar amount. Amounts deducted from a Participant’s Compensation with respect to an Offering Period pursuant to this Section 3.2 shall be deducted each Payday through payroll deduction and credited to the Participant’s Plan Account.  

(c)Following at least one (1) payroll deduction, a Participant may decrease (to as low as zero) the amount deducted from such Participant’s Compensation only once during an Offering Period upon ten (10) calendar days’ prior written notice to the Company. A Participant may not increase the amount deducted from such Participant’s Compensation during an Offering Period.

(d)Notwithstanding the foregoing, upon the termination of an Offering Period, each Participant in such Offering Period shall automatically participate in the immediately following Offering Period at the same payroll deduction percentage or fixed amount as in effect at the termination of the prior Offering Period, unless such Participant delivers to the Company a different election with respect to the successive Offering Period in accordance with Section 3.2(a) hereof, or unless such Participant becomes ineligible for participation in the Plan.

5

Amended & Restated ESPP Sept 4, 2018

 

 

3.3Leave of Absence.  During leaves of absence approved by the Company meeting the requirements of Treasury Regulation Section 1.421-1(h)(2) under the Code, a Participant may continue participation in the Plan by making cash payments to the Company on his or her normal payday equal to his or her authorized payroll deduction.

ARTICLE IV.
PURCHASE OF SHARES

4.1Grant of Option.  Each Participant shall be granted an Option with respect to an Offering Period on the applicable Grant Date. Subject to the limitations of Section 3.1(b) hereof, the number of shares of Common Stock subject to a Participant’s Option shall be determined by dividing (a) such Participant’s payroll deductions accumulated prior to an Exercise Date and retained in the Participant’s Plan Account on such Exercise Date by (b) the applicable Option Price; provided that in no event shall a Participant be permitted to purchase during each Offering Period more than 15,000 shares of Common Stock (subject to any adjustment pursuant to Section 5.2 hereof). The Administrator may, for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that a Participant may purchase during such future Offering Periods. Each Option shall expire on the Exercise Date for the applicable Offering Period immediately after the automatic exercise of the Option in accordance with Section 4.3 hereof, unless such Option terminates earlier in accordance with Article 6 hereof.

4.2Option Price.  The “Option Price” per share of Common Stock to be paid by a Participant upon exercise of the Participant’s Option on the applicable Exercise Date for an Offering Period shall be equal to eighty five percent (85%) of the lesser of the Fair Market Value of a share of Common Stock on (a) the applicable Grant Date and (b) the applicable Exercise Date; provided that in no event shall the Option Price per share of Common Stock be less than the par value per share of the Common Stock.

4.3Purchase of Shares.

(a)On the applicable Exercise Date for an Offering Period, each Participant shall automatically and without any action on such Participant’s part be deemed to have exercised his or her Option to purchase at the applicable per share Option Price the largest number of whole shares of Common Stock which can be purchased with the amount in the Participant’s Plan Account. Any balance less than the per share Option Price that is remaining in the Participant’s Plan Account (after exercise of such Participant’s Option) as of the Exercise Date shall be carried forward to the next Offering Period, unless the Participant has elected to withdraw from the Plan pursuant to Section 6.1 hereof or, pursuant to Section 6.2 hereof, such Participant has ceased to be an Eligible Employee. Any balance not carried forward to the next Offering Period in accordance with the prior sentence promptly shall be refunded to the applicable Participant. For the avoidance of doubt, in no event shall an amount greater than or equal to the per share Option Price as of an Exercise Date be carried forward to the next Offering Period.

(b)As soon as practicable following the applicable Exercise Date, the number of shares of Common Stock purchased by such Participant pursuant to Section 4.3(a) hereof shall be delivered (either in share certificate or book entry form), in the Company’s sole discretion, to either (i) the Participant or (ii) an account established in the Participant’s name at a stock brokerage or other financial services firm designated by the Company. If the Company is required to obtain from any commission or agency authority to issue any such shares of Common Stock, the Company shall seek to obtain such authority. Inability of the Company to obtain from any such commission or agency authority which counsel for the Company deems necessary for the lawful 

6

Amended & Restated ESPP Sept 4, 2018

 

 

issuance of any such shares shall relieve the Company from liability to any Participant except to refund to the Participant such Participant’s Plan Account balance, without interest thereon.

4.4Transferability of Rights.  An Option granted under the Plan shall not be transferable, other than by will or the applicable laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant. No option or interest or right to the Option shall be available to pay off any debts, contracts or engagements of the Participant or his or her successors in interest or shall be subject to disposition by pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempt at disposition of the option shall have no effect.

ARTICLE V.
PROVISIONS RELATING TO COMMON STOCK

5.1Common Stock Reserved.  Subject to adjustment as provided in Section 5.2 hereof, the maximum number of shares of Common Stock that shall be made available for sale under the Plan shall be the sum of (a) 536,242 shares and (b) an annual increase on the first day of each year beginning in 2019 and ending in 2028 equal to the lesser of (i) one percent (1%) of the shares outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares as may be determined by the Board; provided, however, no more than 8,000,000 shares may be issued under the Plan. Shares made available for sale under the Plan may be authorized but unissued shares, treasury shares of Common Stock, or reacquired shares reserved for issuance under the Plan.

5.2Adjustments Upon Changes in Capitalization, Dissolution, Liquidation, Merger or Asset Sale.

(a)Changes in Capitalization.  Subject to any required action by the stockholders of the Company, the number of shares of Common Stock which have been authorized for issuance under the Plan but not yet placed under Option, as well as the price per share and the number of shares of Common Stock covered by each Option under the Plan which has not yet been exercised shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock, or any other increase or decrease in the number of shares of Common Stock effected without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Administrator, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to an Option.

(b)Dissolution or Liquidation.  In the event of the proposed dissolution or liquidation of the Company, the Offering Period then in progress shall be shortened by setting a new Exercise Date (the “New Exercise Date”), and shall terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the Administrator. The New Exercise Date shall be before the date of the Company’s proposed dissolution or liquidation. The Administrator shall notify each Participant in writing, at least ten (10) business days prior to the New Exercise Date, that the Exercise Date for the Participant’s Option has been changed to the New Exercise Date and that the Participant’s Option shall be exercised automatically 

7

Amended & Restated ESPP Sept 4, 2018

 

 

on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 6.1 hereof.  

(c)Merger or Asset Sale.  In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger of the Company with or into another corporation, each outstanding Option shall be assumed or an equivalent Option substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Option, any Offering Periods then in progress shall be shortened by setting a New Exercise Date and any Offering Periods then in progress shall end on the New Exercise Date. The New Exercise Date shall be before the date of the Company’s proposed sale or merger. The Administrator shall notify each Participant in writing, at least ten (10) business days prior to the New Exercise Date, that the Exercise Date for the Participant’s Option has been changed to the New Exercise Date and that the Participant’s Option shall be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 6.1 hereof.

5.3Insufficient Shares.  If the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which Options are to be exercised may exceed the number of shares of Common Stock remaining available for sale under the Plan on such Exercise Date, the Administrator shall make a pro rata allocation of the shares of Common Stock available for issuance on such Exercise Date in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants exercising Options to purchase Common Stock on such Exercise Date, and unless additional shares are authorized for issuance under the Plan, no further Offering Periods shall take place and the Plan shall terminate pursuant to Section 7.5 hereof. If an Offering Period is so terminated, then the balance of the amount credited to the Participant’s Plan Account which has not been applied to the purchase of shares of Common Stock shall be paid to such Participant in one lump sum in cash within thirty (30) days after such Exercise Date, without any interest thereon. 

5.4Rights as Stockholders.  With respect to shares of Common Stock subject to an Option, a Participant shall not be deemed to be a stockholder of the Company and shall not have any of the rights or privileges of a stockholder. A Participant shall have the rights and privileges of a stockholder of the Company when, but not until, shares of Common Stock have been deposited in the designated brokerage account following exercise of his or her Option.

ARTICLE VI.
TERMINATION OF PARTICIPATION

6.1Cessation of Contributions; Voluntary Withdrawal.

(a)A Participant may cease payroll deductions during an Offering Period and elect to withdraw from the Plan by delivering written notice of such election to the Company in such form and at such time prior to the Exercise Date for such Offering Period as may be established by the Administrator (a “Withdrawal Election”). A Participant electing to withdraw from the Plan may elect to either (i) withdraw all of the funds then credited to the Participant’s Plan Account as of the date on which the Withdrawal Election is received by the Company, in which case amounts credited to such Plan Account shall be returned to the Participant in one (1) lump-sum payment in cash within thirty (30) days after such election is received by the Company, without any interest thereon, and the Participant shall cease to participate in the Plan and the Participant’s Option for such Offering Period shall terminate; or (ii) exercise the Option for the maximum number of whole shares of Common Stock on the applicable Exercise Date with any remaining Plan Account balance 

8

Amended & Restated ESPP Sept 4, 2018

 

 

returned to the Participant in one (1) lump-sum payment in cash within thirty (30) days after such Exercise Date, without any interest thereon, and after such exercise cease to participate in the Plan. Upon receipt of a Withdrawal Election, the Participant’s payroll deduction authorization and his or her Option to purchase under the Plan shall terminate.

(b)A participant’s withdrawal from the Plan shall not have any effect upon his or her eligibility to participate in any similar plan which may hereafter be adopted by the Company or in succeeding Offering Periods which commence after the termination of the Offering Period from which the Participant withdraws.

(c)A Participant who ceases contributions to the Plan during any Offering Period shall not be permitted to resume contributions to the Plan during that Offering Period. 

6.2Termination of Eligibility.  Upon a Participant’s ceasing to be an Eligible Employee, for any reason, such Participant’s Option for the applicable Offering Period shall automatically terminate, he or she shall be deemed to have elected to withdraw from the Plan, and such Participant’s Plan Account shall be paid to such Participant or, in the case of his or her death, to the person or persons entitled thereto pursuant to applicable law, within thirty (30) days after such cessation of being an Eligible Employee, without any interest thereon.

ARTICLE VII.
GENERAL PROVISIONS

7.1Administration.  

(a)The Plan shall be administered by the Committee, which shall be composed of members of the Board. The Committee may delegate administrative tasks under the Plan to the services of an Agent and/or Employees to assist in the administration of the Plan, including establishing and maintaining an individual securities account under the Plan for each Participant.

(b)It shall be the duty of the Administrator to conduct the general administration of the Plan in accordance with the provisions of the Plan. The Administrator shall have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i)To establish and terminate Offering Periods;

(ii)To determine when and how Options shall be granted and the provisions and terms of each Offering Period (which need not be identical);

(iii)To select Designated Subsidiaries in accordance with Section 7.2 hereof; and

(iv)To construe and interpret the Plan, the terms of any Offering Period and the terms of the Options and to adopt such rules for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, any Offering Period or any Option, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effect, subject to Section 423 of the Code and the Treasury Regulations thereunder.

9

Amended & Restated ESPP Sept 4, 2018

 

 

(c)The Administrator may adopt rules or procedures relating to the operation and administration of the Plan to accommodate the specific requirements of local laws and procedures. Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding handling of participation elections, payroll deductions, payment of interest, conversion of local currency, payroll tax, withholding procedures and handling of stock certificates which vary with local requirements. In its absolute discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Administrator under the Plan.

(d)The Administrator may adopt sub-plans applicable to particular Designated Subsidiaries or locations, which sub-plans may be designed to be outside the scope of Section 423 of the Code. The rules of such sub-plans may take precedence over other provisions of this Plan, with the exception of Section 5.1 hereof, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan.

(e)All expenses and liabilities incurred by the Administrator in connection with the administration of the Plan shall be borne by the Company. The Administrator may, with the approval of the Committee, employ attorneys, consultants, accountants, appraisers, brokers or other persons. The Administrator, the Company and its officers and directors shall be entitled to rely upon the advice, opinions or valuations of any such persons. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon all Participants, the Company and all other interested persons. No member of the Board or Administrator shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or the options, and all members of the Board or Administrator shall be fully protected by the Company in respect to any such action, determination, or interpretation. 

7.2Designation of Subsidiary Corporations.  The Board or Committee shall designate from among the Subsidiaries, as determined from time to time, the Subsidiary or Subsidiaries that shall constitute Designated Subsidiaries. The Board or Committee may designate a Subsidiary, or terminate the designation of a Subsidiary, without the approval of the stockholders of the Company.

7.3Reports.  Individual accounts shall be maintained for each Participant in the Plan. Statements of Plan Accounts shall be given to Participants at least annually, which statements shall set forth the amounts of payroll deductions, the Option Price, the number of shares purchased and the remaining cash balance, if any.

7.4No Right to Employment.  Nothing in the Plan shall be construed to give any person (including any Participant) the right to remain in the employ of the Company, a Parent or a Subsidiary or to affect the right of the Company, any Parent or any Subsidiary to terminate the employment of any person (including any Participant) at any time, with or without cause, which right is expressly reserved.

7.5Amendment and Termination of the Plan.

(a)The Board may, in its sole discretion, amend, suspend or terminate the Plan at any time and from time to time; provided, however, that without approval of the Company’s stockholders given within twelve (12) months before or after action by the Board, the Plan may not be amended to increase the maximum number of shares of Common Stock subject to the Plan or change the designation or class of Eligible Employees; and provided, further that without approval of 

10

Amended & Restated ESPP Sept 4, 2018

 

 

the Company’s stockholders, the Plan may not be amended in any manner that would cause the Plan to no longer be an “employee stock purchase plan” within the meaning of Section 423(b) of the Code.

(b)In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, to the extent permitted under Section 423 of the Code, in its discretion and, to the extent necessary or desirable, modify or amend the Plan to reduce or eliminate such accounting consequence including, but not limited to:

(i)altering the Option Price for any Offering Period including an Offering Period underway at the time of the change in Option Price;

(ii)shortening any Offering Period so that the Offering Period ends on a new Exercise Date, including an Offering Period underway at the time of the Administrator action; and

(iii)allocating shares of Common Stock.

Such modifications or amendments shall not require stockholder approval or the consent of any Participant.

(c)Upon termination of the Plan, the balance in each Participant’s Plan Account shall be refunded as soon as practicable after such termination, without any interest thereon.

7.6Use of Funds; No Interest Paid.  All funds received by the Company by reason of purchase of Common Stock under the Plan shall be included in the general funds of the Company free of any trust or other restriction and may be used for any corporate purpose. No interest shall be paid to any Participant or credited under the Plan.

7.7Term; Approval by Stockholders.  No Option may be granted during any period of suspension of the Plan or after termination of the Plan. The Plan was approved by the Company’s stockholders on April 20, 2018.

7.8Effect Upon Other Plans.  The adoption of the Plan shall not affect any other compensation or incentive plans in effect for the Company, any Parent or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company, any Parent or any Subsidiary (a) to establish any other forms of incentives or compensation for Employees of the Company or any Parent or any Subsidiary, or (b) to grant or assume Options otherwise than under the Plan in connection with any proper corporate purpose, including, but not by way of limitation, the grant or assumption of options in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business, stock or assets of any corporation, firm or association.

7.9Conformity to Securities Laws.  Notwithstanding any other provision of the Plan, the Plan and the participation in the Plan by any individual who is then subject to Section 16 of the Exchange Act shall be subject to any additional limitations set forth in any applicable exemption rule under Section 16 of the Exchange Act (including any amendment to Rule 16b‐3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, the Plan shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. 

11

Amended & Restated ESPP Sept 4, 2018

 

 

7.10Notice of Disposition of Shares.  Each Participant shall give the Company prompt notice of any disposition or other transfer of any shares of Common Stock, acquired pursuant to the exercise of an Option, if such disposition or transfer is made (a) within two (2) years after the applicable Grant Date or (b) within one (1) year after the transfer of such shares of Common Stock to such Participant upon exercise of such Option. The Company may direct that any certificates evidencing shares acquired pursuant to the Plan refer to such requirement.

7.11Tax Withholding.  The Company or any Parent or any Subsidiary shall be entitled to require payment in cash or deduction from other compensation payable to each Participant of any sums required by federal, state or local tax law to be withheld with respect to any purchase of shares of Common Stock under the Plan or any sale of such shares.

7.12Governing Law.  The Plan and all rights and obligations thereunder shall be construed and enforced in accordance with the laws of the State of Delaware.

7.13Notices.  All notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. 

7.14Conditions To Issuance of Shares. 

(a)Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates or make any book entries evidencing shares of Common Stock pursuant to the exercise of an Option by a Participant, unless and until the Board or the Committee has determined, with advice of counsel, that the issuance of such shares of Common Stock is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any securities exchange or automated quotation system on which the shares of Common Stock are listed or traded, and the shares of Common Stock are covered by an effective registration statement or applicable exemption from registration. In addition to the terms and conditions provided herein, the Board or the Committee may require that a Participant make such reasonable covenants, agreements, and representations as the Board or the Committee, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements.

(b)All certificates for shares of Common Stock delivered pursuant to the Plan and all shares of Common Stock issued pursuant to book entry procedures are subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal, state, or foreign securities or other laws, rules and regulations and the rules of any securities exchange or automated quotation system on which the shares of Common Stock are listed, quoted, or traded. The Committee may place legends on any certificate or book entry evidencing shares of Common Stock to reference restrictions applicable to the shares of Common Stock.

(c)The Committee shall have the right to require any Participant to comply with any timing or other restrictions with respect to the settlement, distribution or exercise of any Option, including a window-period limitation, as may be imposed in the sole discretion of the Committee.

(d)Notwithstanding any other provision of the Plan, unless otherwise determined by the Committee or required by any applicable law, rule or regulation, the Company may, in lieu of delivering to any Participant certificates evidencing shares of Common Stock issued in 

12

Amended & Restated ESPP Sept 4, 2018

 

 

connection with any Option, record the issuance of shares of Common Stock in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).

7.15Equal Rights and Privileges.  Except with respect to sub-plans designed to be outside the scope of Section 423 of the Code, all Eligible Employees of the Company (or of any Designated Subsidiary) shall have equal rights and privileges under this Plan to the extent required under Section 423 of the Code or the regulations promulgated thereunder so that this Plan qualifies as an “employee stock purchase plan” within the meaning of Section 423 of the Code or the Treasury Regulations thereunder. Any provision of this Plan that is inconsistent with Section 423 of the Code or the Treasury Regulations thereunder shall, without further act or amendment by the Company or the Board, be reformed to comply with the equal rights and privileges requirement of Section 423 of the Code or the Treasury Regulations thereunder.  

13

Amended & Restated ESPP Sept 4, 2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]